miR-92aA molecular CRC specific diagnostic marker

MiR-92a (microRNA-92a), a small non-coding RNA, is a newly discovered biomarker with high sensitivity and specificity to CRC. It promotes cell proliferation and migration of colorectal cancer cells by targeting PTEN, KLF4 and downstream p21 genes. Multiple studies found characteristically increased miR-92a level in patients’ stool specimen with CRC or CRC lesions. REColonTM works through detecting miR-92a level directly from CRC cells shed from lining of human colon and eventually excreted in the stool.


A comparative analysis is made between colonoscopy and REColonTM tests of in total 1,241 CRC and normal cases, REColonTM achieves 71.76% sensitivity and 90.07% specificity for CRC diagnosis.

71.76% Sensitivity90.23% Specificity

REColonTM

Colonoscopy

Total

Positive

Negative

Positive

244

88

332

Negative

96

813

909

Total

340

901

1,241

Ø REColonTM Diagnostic Accuracy : 84.96%1,057/1,241

Ø Sensitivity71.76% (244/340)

Ø Specificity90.23% (813/901)



Non-specificity Reaction Evaluation

   

Non-CRC Group

miR-92 neg-

miR-92a pos+

Specificity

Non-CRC group

miR-92 neg-

miR-92a pos+

Specificity

Pancreatic Cancer

20 cases

20

0

100%

Enteritis

45 cases

42

3

93.33%

Bile Duct Cancer

20 cases

19

1

95.00%

Colitis

29 cases

27

2

93.10%

Liver Cancer

20 cases

19

1

95.00%

Peptic ulcer

24 cases

23

 

 

1

95.83%

Oral Cancer

20 cases

19

1

95.00%

Appendicitis

20 cases

19

1

95.00%

Esophageal Cancer

20 cases

20

0

100%

Gastritis

20例)

19

1

95.00%

Gastric Cancer

25 cases

23

2

92.00%





About Us
Product
News
Lessons
Service
Telephone:
0755-86573093
Shenzhen GeneBioHealth Co., Ltd
Fax:(+86)755-86573069   E-mail:service@genebiohealth.com   Address:Buliding A9-2F, Tianliao Industrial Park A, Taoyuan Street, Nanshan District, Shenzhen, China
Copyright ©2018 Shenzhen GeneBioHealth Co., Ltd Copyright 粤ICP备15109924号

Buy online
Follow Wechat